Surgery is frequently the only available treatment modality for recurrent head and neck squamous cell carcinoma (HNSCC) despite increased morbidity and lower success rates compared with surgery in the setting of primary disease.
1,2 In many cases, critical clinical decisions for each patient must be made to determine whether the potential benefits of salvage surgery outweigh its risks, morbidity, and economic costs.